Brief: BrainStorm Cell To Cut About 30% Jobs

Brainstorm Cell Therapeutics

24/10/2023 12:10

Oct 24 (Reuters) - Brainstorm Cell Therapeutics Inc
 BCLI.O :
    * BRAINSTORM CELL THERAPEUTICS ANNOUNCES STRATEGIC
REALIGNMENT
PRIORITIZING NUROWN® FOR THE TREATMENT OF ALS
    * BRAINSTORM CELL THERAPEUTICS INC - RESOURCE CONSUMPTION
WILL BE
REDUCED BY 50% TO ACCELERATE ALS DEVELOPMENT
    * BRAINSTORM CELL THERAPEUTICS INC - PLANS UNDERWAY FOR
REGISTRATIONAL PHASE 3B U.S. CLINICAL TRIAL FOR NUROWN IN ALS
    * BRAINSTORM CELL THERAPEUTICS INC - UNDERTAKING A TARGETED
REDUCTION IN HEADCOUNT OF APPROXIMATELY 30 PERCENT
    * BRAINSTORM CELL THERAPEUTICS INC - WILL REDUCE AND REFOCUS
RESOURCES BY STREAMLINING CLEAN ROOM OPERATIONS
    * BRAINSTORM CELL THERAPEUTICS - AS PART OF STRATEGIC
REALIGNMENT,
DR. KIRK TAYLOR, EVP AND CHIEF MEDICAL OFFICER, WILL BE STEPPING
DOWN FROM HIS POST
    * BRAINSTORM CELL THERAPEUTICS INC - CERTAIN OTHER POSITIONS
THAT
ARE OUTSIDE CURRENT PRIORITIZED SCOPE WILL BE ELIMINATED
    * BRAINSTORM CELL THERAPEUTICS- TO FUND PHASE 3B STUDY, ALS
PRIORITIES, EXPLORING OPTIONS TO RAISE CAPITAL

Source text for Eikon:  ID:nPn79FrsNa 
Further company coverage:  BCLI.O 

 ((Reuters.Briefs@thomsonreuters.com;))